VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
CDXSCodexis, Inc.
$2.57$234M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

CDXS logoCodexis, Inc.(CDXS)Earnings, Financials & Key Ratios

CDXS•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryLife Science Tools and Reagents
AboutCodexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Show more
  • Revenue$70M+18.6%
  • EBITDA-$33M+43.6%
  • Net Income-$44M+32.6%
  • EPS (Diluted)-0.50+43.8%
  • Gross Margin86.73%+19.5%
  • EBITDA Margin-47%+52.5%
  • Operating Margin-54.46%+44.8%
  • Net Margin-62.47%+43.2%
  • ROE-74.88%+11.9%

CDXS Key Insights

Codexis, Inc. (CDXS) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 86 (top 14%)

✗Weaknesses

  • ✗Profits declining 12.9% over 5 years
  • ✗Negative free cash flow
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Shares diluted 18.7% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when CDXS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

CDXS Price & Volume

Codexis, Inc. (CDXS) stock price & volume — 10-year historical chart

Loading chart...

CDXS Growth Metrics

Codexis, Inc. (CDXS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years5.35%
5 Years0.38%
3 Years-20.22%
TTM56.76%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM57.04%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM63.04%

Return on Capital

10 Years-32.89%
5 Years-31.14%
3 Years-42.59%
Last Year-30.93%

CDXS Recent Earnings

Codexis, Inc. (CDXS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$0.10+9.1%
$0.11
Rev
$15M+5.0%
$15M
Q2 2026
Mar 11, 2026
Metric
Actual
Est
EPS
$0.11+1000.0%
$0.01
Rev
$39M+8.6%
$36M
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$0.22-46.7%
$0.15
Rev
$9M-76.0%
$36M
Q3 2025
Aug 13, 2025
Metric
Actual
Est
EPS
$0.16+5.9%
$0.17
Rev
$15M-21.3%
$19M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$0.10vs $0.11+9.1%
$15Mvs $15M+5.0%
Q2 2026Mar 11, 2026
$0.11vs $0.01+1000.0%
$39Mvs $36M+8.6%
Q4 2025Nov 6, 2025
$0.22vs $0.15-46.7%
$9Mvs $36M-76.0%
Q3 2025Aug 13, 2025
$0.16vs $0.17+5.9%
$15Mvs $19M-21.3%
Based on last 12 quarters of dataView full earnings history →

CDXS Peer Comparison

Codexis, Inc. (CDXS) competitors in Life Science Tools and Reagents — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
GEVO logoGEVOGevo, Inc.Direct Competitor374.85M1.54-118.49%-19.38%-7.19%0.36
BEAM logoBEAMBeam Therapeutics Inc.Direct Competitor3.51B34.14-42.15120.01%-49.17%-5.89%0.24
TRMK logoTRMKTrustmark CorporationDirect Competitor2.63B44.6712.0734.75%19.32%10.77%0.53
NUVB logoNUVBNuvation Bio Inc.Product Competitor1.93B5.56-9.276.99%-102.06%-44.1%0.03
RCKT logoRCKTRocket Pharmaceuticals, Inc.Product Competitor365.8M3.35-1.67-70.79%0.09
CRBU logoCRBUCaribou Biosciences, Inc.Product Competitor162.66M1.64-1.0311.66%-11.89%-100.13%0.22
NTLA logoNTLAIntellia Therapeutics, Inc.Product Competitor1.76B15.67-4.1116.92%-5.97%-57.27%0.14
MRK logoMRKMerck & Co., Inc.Supply Chain281.25B113.8715.641.18%28.12%36.14%0.96

Compare CDXS vs Peers

Codexis, Inc. (CDXS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs GEVO

Most directly comparable listed peer for CDXS.

Scale Benchmark

vs LLY

Larger-name benchmark to compare CDXS against a more recognizable public peer.

Peer Set

Compare Top 5

vs GEVO, BEAM, TRMK, NUVB

CDXS Income Statement

Codexis, Inc. (CDXS) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
50.02M60.59M68.46M69.06M104.75M138.59M70.14M59.34M70.39M78.09M
Revenue Growth %
2.43%21.13%12.98%0.87%51.69%32.3%-49.39%-15.39%18.61%56.76%
Cost of Goods Sold
14.33M12.62M15.63M13.74M22.21M38.03M12.81M16.29M9.34M12.54M
COGS % of Revenue
28.64%20.83%22.83%19.9%21.2%27.44%18.26%27.45%13.27%-
Gross Profit
35.7M▲ 0%
47.97M▲ 34.4%
52.83M▲ 10.1%
55.31M▲ 4.7%
82.55M▲ 49.2%
100.56M▲ 21.8%
57.33M▼ 43.0%
43.06M▼ 24.9%
61.05M▲ 41.8%
65.55M▲ 0%
Gross Margin %
71.36%79.17%77.17%80.1%78.8%72.56%81.74%72.55%86.73%83.94%
Gross Profit Growth %
-8.67%34.39%10.11%4.71%49.23%21.82%-42.98%-24.9%41.79%-
Operating Expenses
58.67M59.27M65.38M79.23M105.24M135.44M125.4M101.58M99.38M91.44M
OpEx % of Revenue
117.28%97.81%95.5%114.74%100.47%97.73%178.78%171.16%141.19%-
Selling, General & Admin
29.01M29.29M31.5M35.05M49.32M52.17M53.25M55.15M47.07M43.75M
SG&A % of Revenue
57.99%48.34%46.02%50.75%47.08%37.64%75.92%92.93%66.88%-
Research & Development
29.66M29.98M33.87M44.19M55.92M80.1M58.88M46.26M52.31M47.7M
R&D % of Revenue
59.29%49.47%49.48%63.98%53.38%57.8%83.95%77.96%74.31%-
Other Operating Expenses
-92K-291K0003.17M13.27M165K00
Operating Income
-22.97M▲ 0%
-11.29M▲ 50.8%
-12.55M▼ 11.1%
-23.92M▼ 90.6%
-22.7M▲ 5.1%
-34.88M▼ 53.7%
-68.07M▼ 95.1%
-58.52M▲ 14.0%
-38.33M▲ 34.5%
-25.89M▲ 0%
Operating Margin %
-45.92%-18.64%-18.33%-34.64%-21.67%-25.17%-97.04%-98.61%-54.46%-33.15%
Operating Income Growth %
-168.22%50.83%-11.1%-90.61%5.11%-53.68%-95.15%14.03%34.5%-
EBITDA
-21.93M-10.15M-7.99M-19.37M-16.75M-29.48M-62.55M-58.68M-33.08M-17.32M
EBITDA Margin %
-43.84%-16.75%-11.67%-28.04%-15.99%-21.27%-89.18%-98.89%-47%-22.18%
EBITDA Growth %
-445.74%53.72%21.25%-142.32%13.51%-75.99%-112.19%6.18%43.62%70.66%
D&A (Non-Cash Add-back)
1.04M1.15M4.56M4.55M5.95M5.4M5.52M-165K5.25M8.57M
EBIT
-22.97M-11.29M-12.55M-23.92M-22.7M-31.71M-54.8M-58.35M-39.11M-25.25M
Net Interest Income
147K671K1.29M405K459K1.44M4.17M3.67M-2.19M1.25M
Interest Income
147K671K1.29M405K459K1.44M4.17M3.67M2.63M2.54M
Interest Expense
000000004.81M1.29M
Other Income/Expense
55K380K631K249K1.61M1.56M-8.1M-6.72M-5.59M-6.03M
Pretax Income
-22.91M▲ 0%
-10.91M▲ 52.4%
-11.92M▼ 9.2%
-23.67M▼ 98.6%
-21.09M▲ 10.9%
-33.32M▼ 58.0%
-76.17M▼ 128.6%
-65.24M▲ 14.3%
-43.93M▲ 32.7%
-31.92M▲ 0%
Pretax Margin %
-45.81%-18.01%-17.41%-34.28%-20.13%-24.04%-108.59%-109.94%-62.41%-40.87%
Income Tax
81K-37K17K339K189K276K69K34K47K72K
Effective Tax Rate %
-0.35%0.34%-0.14%-1.43%-0.9%-0.83%-0.09%-0.05%-0.11%-0.23%
Net Income
-23M▲ 0%
-10.88M▲ 52.7%
-11.94M▼ 9.7%
-24.01M▼ 101.2%
-21.28M▲ 11.4%
-33.59M▼ 57.9%
-76.24M▼ 127.0%
-65.28M▲ 14.4%
-43.97M▲ 32.6%
-31.99M▲ 0%
Net Margin %
-45.97%-17.95%-17.43%-34.77%-20.31%-24.24%-108.69%-109.99%-62.47%-40.96%
Net Income Growth %
-168.71%52.7%-9.72%-101.17%11.37%-57.86%-126.96%14.38%32.63%57.04%
Net Income (Continuing)
-23M-10.88M-11.94M-24.01M-21.28M-33.59M-76.24M-65.28M-43.97M-31.99M
Discontinued Operations
0000000000
Minority Interest
0000000000
EPS (Diluted)
-0.50▲ 0%
-0.21▲ 58.0%
-0.21▲ 0.0%
-0.40▼ 90.5%
-0.33▲ 17.5%
-0.51▼ 54.5%
-1.12▼ 119.6%
-0.89▲ 20.5%
-0.50▲ 43.8%
-0.35▲ 0%
EPS Growth %
-138.1%58%0%-90.48%17.5%-54.55%-119.61%20.54%43.82%63.04%
EPS (Basic)
-0.50-0.21-0.21-0.40-0.33-0.51-1.12-0.89-0.50-
Diluted Shares Outstanding
46.23M52.2M56.52M59.36M64.57M65.34M68.13M73.41M87.14M90.77M
Basic Shares Outstanding
46.23M52.2M56.52M59.36M64.57M65.34M68.13M73.41M87.14M90.77M
Dividend Payout Ratio
----------

CDXS Balance Sheet

Codexis, Inc. (CDXS) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
45.04M67.2M114.2M184.42M161.89M162.89M93.47M98.77M96.82M79.65M
Cash & Short-Term Investments
31.22M53.04M90.5M150.12M116.8M113.98M65.12M73.46M78.21M65.56M
Cash Only
31.22M53.04M90.5M149.12M116.8M113.98M65.12M19.26M50.79M37M
Short-Term Investments
0001M00054.19M27.42M28.57M
Accounts Receivable
11.8M13.5M20.16M29.29M37.65M40.87M19.93M18.88M10.73M8.03M
Days Sales Outstanding
86.181.33107.46154.8131.19107.65103.7116.1555.6452.55
Inventory
1.04M589K371K964K1.16M2.03M2.69M1.8M1.82M2M
Days Inventory Outstanding
26.3917.048.6625.619.0619.4776.5140.3171.0256.02
Other Current Assets
984K0661K638K579K521K5.74M4.63M6.06M400K
Total Non-Current Assets
8.59M11.09M34.87M37.22M84.5M87.5M43.09M50.24M50.98M49.72M
Property, Plant & Equipment
2.81M4.76M30.39M31.18M65.46M61.88M28.62M42.9M43.52M42.15M
Fixed Asset Turnover
17.77x12.73x2.25x2.22x1.60x2.24x2.45x1.38x1.62x1.85x
Goodwill
3.24M3.24M3.24M3.24M3.24M3.24M2.46M2.46M2.46M2.46M
Intangible Assets
0000000000
Long-Term Investments
671K588K01.45M14M20.51M9.7M2.8M2.5M14.07M
Other Non-Current Assets
1.86M2.5M1.24M1.36M1.79M1.87M2.31M2.08M2.5M594K
Total Assets
53.63M▲ 0%
78.28M▲ 46.0%
149.07M▲ 90.4%
221.65M▲ 48.7%
246.38M▲ 11.2%
250.39M▲ 1.6%
136.56M▼ 45.5%
149.01M▲ 9.1%
147.8M▼ 0.8%
129.37M▲ 0%
Asset Turnover
0.93x0.77x0.46x0.31x0.43x0.55x0.51x0.40x0.48x0.58x
Asset Growth %
50.43%45.98%90.43%48.68%11.16%1.63%-45.46%9.12%-0.81%-12.06%
Total Current Liabilities
24.95M17.11M15.39M24.98M33.37M49.07M35.83M23.65M25.32M14.85M
Accounts Payable
3.54M3.05M2.62M2.97M3M3.25M5.95M2.84M1.55M2.13M
Days Payables Outstanding
90.3188.2161.278.8949.2231.15169.4663.660.7455.12
Short-Term Debt
0000000003.3M
Deferred Revenue (Current)
12.29M3.94M57K1.82M2.59M13.73M10.12M350K7.01M8.27M
Other Current Liabilities
4.36M5.8M5M10.27M11.12M11.45M11.25M11.41M13.81M3.2M
Current Ratio
1.81x3.93x7.42x7.38x4.85x3.32x2.61x4.18x3.82x5.36x
Quick Ratio
1.76x3.89x7.40x7.34x4.82x3.28x2.53x4.10x3.75x5.23x
Cash Conversion Cycle
22.1810.1554.92101.52101.0495.9710.7592.8665.9253.45
Total Non-Current Liabilities
4.13M4.86M28.17M26.56M48.62M56.53M14.12M58.44M71.95M71.29M
Long-Term Debt
000000028.91M40.1M40.48M
Capital Lease Obligations
302K61K24.95M22.32M43.56M38.28M12.24M28.16M30.16M111.68M
Deferred Tax Liabilities
0000000000
Other Non-Current Liabilities
2.32M1.45M1.23M1.27M1.31M1.37M1.23M1.27M1.33M1.33M
Total Liabilities
29.08M21.98M43.56M51.54M81.99M105.6M49.95M82.08M97.27M86.14M
Total Debt
302K61K26.12M24.95M47.65M43.64M16.02M59.9M73.21M72.9M
Net Debt
-30.92M-52.98M-64.38M-124.17M-69.14M-70.35M-49.09M40.63M22.41M35.91M
Debt / Equity
0.01x0.00x0.25x0.15x0.29x0.30x0.19x0.89x1.45x1.69x
Debt / EBITDA
----------4.21x
Net Debt / EBITDA
----------2.07x
Interest Coverage
---------8.13x-19.55x
Total Equity
24.55M▲ 0%
56.31M▲ 129.4%
105.52M▲ 87.4%
170.1M▲ 61.2%
164.39M▼ 3.4%
144.8M▼ 11.9%
86.61M▼ 40.2%
66.93M▼ 22.7%
50.53M▼ 24.5%
43.23M▲ 0%
Equity Growth %
28.53%129.38%87.4%61.21%-3.36%-11.92%-40.18%-22.73%-24.5%-94.34%
Book Value per Share
0.531.081.872.872.552.221.270.910.580.48
Total Shareholders' Equity
24.55M56.31M105.52M170.1M164.39M144.8M86.61M66.93M50.53M43.23M
Common Stock
5K5K6K6K6K6K7K8K9K9K
Retained Earnings
-315.06M-330.47M-342.41M-366.42M-387.7M-421.29M-497.53M-562.81M-606.78M-615.48M
Treasury Stock
0000000000
Accumulated OCI
-472K00000052K8K-11K
Minority Interest
0000000000

CDXS Cash Flow Statement

Codexis, Inc. (CDXS) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-8.76M-14.09M-12.56M-16.46M-14.27M11.28M-52.64M-49.41M-19.38M-18.73M
Operating CF Margin %
-17.52%-23.26%-18.35%-23.84%-13.62%8.14%-75.04%-83.26%-27.53%-
Operating CF Growth %
-224.44%-60.84%10.88%-31.08%13.34%179.09%-566.48%6.13%60.79%219.72%
Net Income
-23M-10.88M-11.94M-24.01M-21.28M-33.59M-76.24M-65.28M-43.97M-31.99M
Depreciation & Amortization
1.04M1.15M4.56M4.55M5.95M10.25M9.92M4.95M5.25M6.75M
Stock-Based Compensation
7.09M7.89M6.94M7.73M11.59M14.53M9.97M13.09M9.62M6.16M
Deferred Taxes
9K00-900K-2.88M00000
Other Non-Cash Items
-207K91K525K55K-19K-1.48M21.93M9.85M3.31M4.93M
Working Capital Changes
6.3M-12.34M-12.65M-3.89M-7.62M21.57M-18.22M-12.02M6.42M-4.58M
Change in Receivables
-5.65M960K2.52M-12.32M-15.57M-3.23M20.25M1.25M8.51M3.56M
Change in Inventory
-210K447K217K-593K-196K-869K-656K886K-19K-220K
Change in Payables
-801K-524K-428K101K268K207K2.29M-2.57M-1.29M-3.04M
Cash from Investing
-908K-2.77M-3.67M-5.75M-21.42M-13.58M-4.86M-56.98M23.5M10.62M
Capital Expenditures
-985K-2.77M-3.73M-3.75M-13.83M-8.31M-4.42M-4.3M-4.47M-3.39M
CapEx % of Revenue
1.97%4.57%5.45%5.43%13.2%5.99%6.3%7.25%6.35%4.34%
Acquisitions
2K2K3K036K29K751K87K5K8K
Investments
----------
Other Investing
77K2K3K036K29K-440K00-4K
Cash from Financing
21.65M38.57M53.96M80.81M3.77M-575K8.17M60.52M27.93M26.83M
Debt Issued (Net)
-175K-238K-242K-60K00029.52M9.89M9.9M
Equity Issued (Net)
23.78M37.5M50M86.25M4.97M913K8.65M31.32M18.03M16.93M
Dividends Paid
0000000000
Share Repurchases
0000000000
Other Financing
-1.96M1.31M4.2M-5.38M-1.21M-1.49M-485K-318K0-3K
Net Change in Cash
11.98M▲ 0%
21.71M▲ 81.2%
37.74M▲ 73.8%
58.6M▲ 55.3%
-31.92M▼ 154.5%
-2.87M▲ 91.0%
-49.33M▼ 1619.4%
-45.87M▲ 7.0%
32.05M▲ 169.9%
23.69M▲ 0%
Free Cash Flow
-9.75M▲ 0%
-16.86M▼ 73.0%
-16.29M▲ 3.4%
-20.21M▼ 24.1%
-28.09M▼ 39.0%
2.98M▲ 110.6%
-57.06M▼ 2016.6%
-53.72M▲ 5.9%
-23.85M▲ 55.6%
-22.12M▲ 0%
FCF Margin %
-19.49%-27.83%-23.8%-29.27%-26.82%2.15%-81.34%-90.51%-33.88%-28.32%
FCF Growth %
-171.61%-72.98%3.39%-24.08%-39%110.6%-2016.56%5.86%55.6%63.04%
FCF per Share
-0.21-0.32-0.29-0.34-0.440.05-0.84-0.73-0.27-0.24
FCF Conversion (FCF/Net Income)
0.38x1.30x1.05x0.69x0.67x-0.34x0.69x0.76x0.44x0.69x
Interest Paid
141K84K49K52K14K34K44K2.57M00
Taxes Paid
32K5K5K312K102K100K194K17K00

CDXS Key Ratios

Codexis, Inc. (CDXS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
-105.38%-26.91%-14.75%-17.42%-12.72%-21.73%-65.89%-85.03%-74.88%-68.09%
Return on Invested Capital (ROIC)
--254.54%-42.33%-41.21%-24.11%-30.83%-91.19%-60.5%-31.85%-23.45%
Gross Margin
71.36%79.17%77.17%80.1%78.8%72.56%81.74%72.55%86.73%83.94%
Net Margin
-45.97%-17.95%-17.43%-34.77%-20.31%-24.24%-108.69%-109.99%-62.47%-40.96%
Debt / Equity
0.01x0.00x0.25x0.15x0.29x0.30x0.19x0.89x1.45x1.69x
Interest Coverage
---------8.13x-19.55x
FCF Conversion
0.38x1.30x1.05x0.69x0.67x-0.34x0.69x0.76x0.44x0.69x
Revenue Growth
2.43%21.13%12.98%0.87%51.69%32.3%-49.39%-15.39%18.61%56.76%
Related:CDXS Dividend History·CDXS Revenue History·CDXS Price History·CDXS P/E History·CDXS Financial Ratios·CDXS Institutional Holders

CDXS SEC Filings & Documents

Codexis, Inc. (CDXS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 7, 2026·SEC

Material company update

Apr 14, 2026·SEC

Material company update

Mar 11, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 11, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 28, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 13, 2025·SEC

CDXS Frequently Asked Questions

Codexis, Inc. (CDXS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Codexis, Inc. (CDXS) reported $78.1M in revenue for fiscal year 2025. This represents a 544% increase from $12.1M in 2006.

Codexis, Inc. (CDXS) grew revenue by 18.6% over the past year. This is strong growth.

Codexis, Inc. (CDXS) reported a net loss of $32.0M for fiscal year 2025.

Dividend & Returns

Codexis, Inc. (CDXS) has a return on equity (ROE) of -74.9%. Negative ROE indicates the company is unprofitable.

Codexis, Inc. (CDXS) had negative free cash flow of $22.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in CDXS back in 2006?

Total return calculator · dividends reinvested · 20+ years of data

See returns →

How much would $100/month in CDXS be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →